Loading…
Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial
Currently, there are no valid clinical or biological markers to personalize the treatment of depression. Recent evidence suggests that body mass index (BMI) may guide the selection of antidepressant medications with different mechanisms of action. Combining Medications to Enhance Depression Outcomes...
Saved in:
| Published in: | Journal of affective disorders 2018-07, Vol.234, p.34-37 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c451t-12999c1915b59c6b92eedc060891a32b35c653d600564ac7c4be975feb3b94d03 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c451t-12999c1915b59c6b92eedc060891a32b35c653d600564ac7c4be975feb3b94d03 |
| container_end_page | 37 |
| container_issue | |
| container_start_page | 34 |
| container_title | Journal of affective disorders |
| container_volume | 234 |
| creator | Jha, Manish K. Wakhlu, Shereen Dronamraju, Neha Minhajuddin, Abu Greer, Tracy L. Trivedi, Madhukar H. |
| description | Currently, there are no valid clinical or biological markers to personalize the treatment of depression. Recent evidence suggests that body mass index (BMI) may guide the selection of antidepressant medications with different mechanisms of action.
Combining Medications to Enhance Depression Outcomes (CO-MED) trial participants with BMI measurement (n = 662) were categorized as normal- or underweight ( |
| doi_str_mv | 10.1016/j.jad.2018.02.089 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6312180</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165032717322826</els_id><sourcerecordid>2012912095</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-12999c1915b59c6b92eedc060891a32b35c653d600564ac7c4be975feb3b94d03</originalsourceid><addsrcrecordid>eNp9kc1u1DAURi0EokPhAdggL9kk3OvEyRgkJDS0gFTUDbC1HPumeJTEg-0Z0bfHoykFNqxsyed8vj-MPUeoEbB7ta23xtUCcF2DqGGtHrAVyr6phMT-IVsVRlbQiP6MPUlpCwCd6uExOxNKCqFaXLHDNzN5Z7JfbvguUpUjmTzTkvkQ3C2fTUrcL45-cpP4HBxFk0PkYeRmyd5RcVIqV_5HDPtsw0zpNb8sZglOfIxh5pvr6vPF-wJ6Mz1lj0YzJXp2d56zr5cXXzYfq6vrD582764q20rMFQqllEWFcpDKdoMSRM5CV1pF04ihkbaTjesAZNca29t2INXLkYZmUK2D5py9PeXu9sNc1FJfNJPeRT-beKuD8frfl8V_1zfhoLsGBa6PAS_vAmL4saeU9eyTpWkyC4V90mX4QqEAJQuKJ9TGkFKk8f4bBH3cl97qsq-jstYgdGmiOC_-ru_e-L2gArw5AVSmdPAUdbKeFkvOR7JZu-D_E_8LSjaoUw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2012912095</pqid></control><display><type>article</type><title>Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial</title><source>ScienceDirect Freedom Collection</source><creator>Jha, Manish K. ; Wakhlu, Shereen ; Dronamraju, Neha ; Minhajuddin, Abu ; Greer, Tracy L. ; Trivedi, Madhukar H.</creator><creatorcontrib>Jha, Manish K. ; Wakhlu, Shereen ; Dronamraju, Neha ; Minhajuddin, Abu ; Greer, Tracy L. ; Trivedi, Madhukar H.</creatorcontrib><description>Currently, there are no valid clinical or biological markers to personalize the treatment of depression. Recent evidence suggests that body mass index (BMI) may guide the selection of antidepressant medications with different mechanisms of action.
Combining Medications to Enhance Depression Outcomes (CO-MED) trial participants with BMI measurement (n = 662) were categorized as normal- or underweight (<25), overweight (25-<30), obese I (30-<35), and obese II+ (≥35). Logistic regression analysis with remission as the dependent variable and treatment arm-by-BMI category interaction as the primary independent variable was used to evaluate if BMI differentially predicted response to escitalopram (SSRI) monotherapy, bupropion-escitalopram combination, or venlafaxine-mirtazapine combination, after controlling for gender and baseline depression severity.
Remission rates among the three treatment arms differed on the basis of pre-treatment BMI (chi-square=12.80, degrees of freedom=6, p = .046). Normal- or under-weight participants were less likely to remit with the bupropion-SSRI combination (26.8%) than SSRI monotherapy (37.3%, number needed to treat or NNT = 9.5) or venlafaxine-mirtazapine combination (44.4%, NNT = 5.7). Conversely, obese II+ participants were more likely to remit with bupropion-SSRI (47.4%) than SSRI monotherapy (28.6%, NNT = 5.3) or venlafaxine-mirtazapine combination (37.7%, NNT = 10.3). Remission rates did not differ among overweight and obese I participants.
Secondary analysis, higher rates of obesity than the general population.
Antidepressant selection in clinical practice can be personalized with BMI measurements. Bupropion-SSRI combination should be avoided in normal- or under-weight depressed outpatients as compared to SSRI monotherapy and venlafaxine-mirtazapine combination and preferred in those with BMI≥35.
•Antidepressant selection in clinical practice can be personalized with BMI measurements.•Outpatients have different reactions to Bupropion-SSRI combination depending upon BMI.•Pre-treatment BMI can differentially predict outcomes to a combination of bupropion-SSRI versus SSRI monotherapy and other combinations.</description><identifier>ISSN: 0165-0327</identifier><identifier>ISSN: 1573-2517</identifier><identifier>EISSN: 1573-2517</identifier><identifier>DOI: 10.1016/j.jad.2018.02.089</identifier><identifier>PMID: 29522941</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adult ; Antidepressant medications ; Antidepressive Agents, Second-Generation - therapeutic use ; Antidepressive Agents, Tricyclic - therapeutic use ; Biomarkers ; Body Mass Index ; Bupropion - therapeutic use ; Citalopram - therapeutic use ; Depression - drug therapy ; Depressive Disorder, Major - drug therapy ; Drug Combinations ; Drug Therapy, Combination ; Female ; Humans ; Major depressive disorder ; Male ; Mianserin - analogs & derivatives ; Mianserin - therapeutic use ; Middle Aged ; Mirtazapine ; Moderator ; Obesity ; Overweight - complications ; Patient Selection ; Treatment Outcome ; Treatment selection ; Venlafaxine Hydrochloride - therapeutic use</subject><ispartof>Journal of affective disorders, 2018-07, Vol.234, p.34-37</ispartof><rights>2018</rights><rights>Copyright © 2018. Published by Elsevier B.V.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-12999c1915b59c6b92eedc060891a32b35c653d600564ac7c4be975feb3b94d03</citedby><cites>FETCH-LOGICAL-c451t-12999c1915b59c6b92eedc060891a32b35c653d600564ac7c4be975feb3b94d03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29522941$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jha, Manish K.</creatorcontrib><creatorcontrib>Wakhlu, Shereen</creatorcontrib><creatorcontrib>Dronamraju, Neha</creatorcontrib><creatorcontrib>Minhajuddin, Abu</creatorcontrib><creatorcontrib>Greer, Tracy L.</creatorcontrib><creatorcontrib>Trivedi, Madhukar H.</creatorcontrib><title>Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial</title><title>Journal of affective disorders</title><addtitle>J Affect Disord</addtitle><description>Currently, there are no valid clinical or biological markers to personalize the treatment of depression. Recent evidence suggests that body mass index (BMI) may guide the selection of antidepressant medications with different mechanisms of action.
Combining Medications to Enhance Depression Outcomes (CO-MED) trial participants with BMI measurement (n = 662) were categorized as normal- or underweight (<25), overweight (25-<30), obese I (30-<35), and obese II+ (≥35). Logistic regression analysis with remission as the dependent variable and treatment arm-by-BMI category interaction as the primary independent variable was used to evaluate if BMI differentially predicted response to escitalopram (SSRI) monotherapy, bupropion-escitalopram combination, or venlafaxine-mirtazapine combination, after controlling for gender and baseline depression severity.
Remission rates among the three treatment arms differed on the basis of pre-treatment BMI (chi-square=12.80, degrees of freedom=6, p = .046). Normal- or under-weight participants were less likely to remit with the bupropion-SSRI combination (26.8%) than SSRI monotherapy (37.3%, number needed to treat or NNT = 9.5) or venlafaxine-mirtazapine combination (44.4%, NNT = 5.7). Conversely, obese II+ participants were more likely to remit with bupropion-SSRI (47.4%) than SSRI monotherapy (28.6%, NNT = 5.3) or venlafaxine-mirtazapine combination (37.7%, NNT = 10.3). Remission rates did not differ among overweight and obese I participants.
Secondary analysis, higher rates of obesity than the general population.
Antidepressant selection in clinical practice can be personalized with BMI measurements. Bupropion-SSRI combination should be avoided in normal- or under-weight depressed outpatients as compared to SSRI monotherapy and venlafaxine-mirtazapine combination and preferred in those with BMI≥35.
•Antidepressant selection in clinical practice can be personalized with BMI measurements.•Outpatients have different reactions to Bupropion-SSRI combination depending upon BMI.•Pre-treatment BMI can differentially predict outcomes to a combination of bupropion-SSRI versus SSRI monotherapy and other combinations.</description><subject>Adult</subject><subject>Antidepressant medications</subject><subject>Antidepressive Agents, Second-Generation - therapeutic use</subject><subject>Antidepressive Agents, Tricyclic - therapeutic use</subject><subject>Biomarkers</subject><subject>Body Mass Index</subject><subject>Bupropion - therapeutic use</subject><subject>Citalopram - therapeutic use</subject><subject>Depression - drug therapy</subject><subject>Depressive Disorder, Major - drug therapy</subject><subject>Drug Combinations</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Major depressive disorder</subject><subject>Male</subject><subject>Mianserin - analogs & derivatives</subject><subject>Mianserin - therapeutic use</subject><subject>Middle Aged</subject><subject>Mirtazapine</subject><subject>Moderator</subject><subject>Obesity</subject><subject>Overweight - complications</subject><subject>Patient Selection</subject><subject>Treatment Outcome</subject><subject>Treatment selection</subject><subject>Venlafaxine Hydrochloride - therapeutic use</subject><issn>0165-0327</issn><issn>1573-2517</issn><issn>1573-2517</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1DAURi0EokPhAdggL9kk3OvEyRgkJDS0gFTUDbC1HPumeJTEg-0Z0bfHoykFNqxsyed8vj-MPUeoEbB7ta23xtUCcF2DqGGtHrAVyr6phMT-IVsVRlbQiP6MPUlpCwCd6uExOxNKCqFaXLHDNzN5Z7JfbvguUpUjmTzTkvkQ3C2fTUrcL45-cpP4HBxFk0PkYeRmyd5RcVIqV_5HDPtsw0zpNb8sZglOfIxh5pvr6vPF-wJ6Mz1lj0YzJXp2d56zr5cXXzYfq6vrD582764q20rMFQqllEWFcpDKdoMSRM5CV1pF04ihkbaTjesAZNca29t2INXLkYZmUK2D5py9PeXu9sNc1FJfNJPeRT-beKuD8frfl8V_1zfhoLsGBa6PAS_vAmL4saeU9eyTpWkyC4V90mX4QqEAJQuKJ9TGkFKk8f4bBH3cl97qsq-jstYgdGmiOC_-ru_e-L2gArw5AVSmdPAUdbKeFkvOR7JZu-D_E_8LSjaoUw</recordid><startdate>20180701</startdate><enddate>20180701</enddate><creator>Jha, Manish K.</creator><creator>Wakhlu, Shereen</creator><creator>Dronamraju, Neha</creator><creator>Minhajuddin, Abu</creator><creator>Greer, Tracy L.</creator><creator>Trivedi, Madhukar H.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180701</creationdate><title>Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial</title><author>Jha, Manish K. ; Wakhlu, Shereen ; Dronamraju, Neha ; Minhajuddin, Abu ; Greer, Tracy L. ; Trivedi, Madhukar H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-12999c1915b59c6b92eedc060891a32b35c653d600564ac7c4be975feb3b94d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Antidepressant medications</topic><topic>Antidepressive Agents, Second-Generation - therapeutic use</topic><topic>Antidepressive Agents, Tricyclic - therapeutic use</topic><topic>Biomarkers</topic><topic>Body Mass Index</topic><topic>Bupropion - therapeutic use</topic><topic>Citalopram - therapeutic use</topic><topic>Depression - drug therapy</topic><topic>Depressive Disorder, Major - drug therapy</topic><topic>Drug Combinations</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Major depressive disorder</topic><topic>Male</topic><topic>Mianserin - analogs & derivatives</topic><topic>Mianserin - therapeutic use</topic><topic>Middle Aged</topic><topic>Mirtazapine</topic><topic>Moderator</topic><topic>Obesity</topic><topic>Overweight - complications</topic><topic>Patient Selection</topic><topic>Treatment Outcome</topic><topic>Treatment selection</topic><topic>Venlafaxine Hydrochloride - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jha, Manish K.</creatorcontrib><creatorcontrib>Wakhlu, Shereen</creatorcontrib><creatorcontrib>Dronamraju, Neha</creatorcontrib><creatorcontrib>Minhajuddin, Abu</creatorcontrib><creatorcontrib>Greer, Tracy L.</creatorcontrib><creatorcontrib>Trivedi, Madhukar H.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of affective disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jha, Manish K.</au><au>Wakhlu, Shereen</au><au>Dronamraju, Neha</au><au>Minhajuddin, Abu</au><au>Greer, Tracy L.</au><au>Trivedi, Madhukar H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial</atitle><jtitle>Journal of affective disorders</jtitle><addtitle>J Affect Disord</addtitle><date>2018-07-01</date><risdate>2018</risdate><volume>234</volume><spage>34</spage><epage>37</epage><pages>34-37</pages><issn>0165-0327</issn><issn>1573-2517</issn><eissn>1573-2517</eissn><abstract>Currently, there are no valid clinical or biological markers to personalize the treatment of depression. Recent evidence suggests that body mass index (BMI) may guide the selection of antidepressant medications with different mechanisms of action.
Combining Medications to Enhance Depression Outcomes (CO-MED) trial participants with BMI measurement (n = 662) were categorized as normal- or underweight (<25), overweight (25-<30), obese I (30-<35), and obese II+ (≥35). Logistic regression analysis with remission as the dependent variable and treatment arm-by-BMI category interaction as the primary independent variable was used to evaluate if BMI differentially predicted response to escitalopram (SSRI) monotherapy, bupropion-escitalopram combination, or venlafaxine-mirtazapine combination, after controlling for gender and baseline depression severity.
Remission rates among the three treatment arms differed on the basis of pre-treatment BMI (chi-square=12.80, degrees of freedom=6, p = .046). Normal- or under-weight participants were less likely to remit with the bupropion-SSRI combination (26.8%) than SSRI monotherapy (37.3%, number needed to treat or NNT = 9.5) or venlafaxine-mirtazapine combination (44.4%, NNT = 5.7). Conversely, obese II+ participants were more likely to remit with bupropion-SSRI (47.4%) than SSRI monotherapy (28.6%, NNT = 5.3) or venlafaxine-mirtazapine combination (37.7%, NNT = 10.3). Remission rates did not differ among overweight and obese I participants.
Secondary analysis, higher rates of obesity than the general population.
Antidepressant selection in clinical practice can be personalized with BMI measurements. Bupropion-SSRI combination should be avoided in normal- or under-weight depressed outpatients as compared to SSRI monotherapy and venlafaxine-mirtazapine combination and preferred in those with BMI≥35.
•Antidepressant selection in clinical practice can be personalized with BMI measurements.•Outpatients have different reactions to Bupropion-SSRI combination depending upon BMI.•Pre-treatment BMI can differentially predict outcomes to a combination of bupropion-SSRI versus SSRI monotherapy and other combinations.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>29522941</pmid><doi>10.1016/j.jad.2018.02.089</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-0327 |
| ispartof | Journal of affective disorders, 2018-07, Vol.234, p.34-37 |
| issn | 0165-0327 1573-2517 1573-2517 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6312180 |
| source | ScienceDirect Freedom Collection |
| subjects | Adult Antidepressant medications Antidepressive Agents, Second-Generation - therapeutic use Antidepressive Agents, Tricyclic - therapeutic use Biomarkers Body Mass Index Bupropion - therapeutic use Citalopram - therapeutic use Depression - drug therapy Depressive Disorder, Major - drug therapy Drug Combinations Drug Therapy, Combination Female Humans Major depressive disorder Male Mianserin - analogs & derivatives Mianserin - therapeutic use Middle Aged Mirtazapine Moderator Obesity Overweight - complications Patient Selection Treatment Outcome Treatment selection Venlafaxine Hydrochloride - therapeutic use |
| title | Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T08%3A53%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Validating%20pre-treatment%20body%20mass%20index%20as%20moderator%20of%20antidepressant%20treatment%20outcomes:%20Findings%20from%20CO-MED%20trial&rft.jtitle=Journal%20of%20affective%20disorders&rft.au=Jha,%20Manish%20K.&rft.date=2018-07-01&rft.volume=234&rft.spage=34&rft.epage=37&rft.pages=34-37&rft.issn=0165-0327&rft.eissn=1573-2517&rft_id=info:doi/10.1016/j.jad.2018.02.089&rft_dat=%3Cproquest_pubme%3E2012912095%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c451t-12999c1915b59c6b92eedc060891a32b35c653d600564ac7c4be975feb3b94d03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2012912095&rft_id=info:pmid/29522941&rfr_iscdi=true |